Quick Answer
Oncotelic Therapeutics, Inc. reported Stockholders Equity of $8.25 million for the year ending 2024.
- Oncotelic Therapeutics, Inc. showed a decrease of -32.0% in Stockholders Equity from 2023 to 2024.
- This data is from Oncotelic Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2008 to 2024 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $7.22 million | Q3 2011: $10.40 million | Q1 2012: $7.51 million | Q2 2012: $6.12 million | Q3 2012: $5.62 million | Q1 2013: $4.35 million | Q2 2013: $7.41 million | Q3 2013: $7.71 million | Q1 2014: $23.85 million | Q2 2014: $34.90 million | Q3 2014: $31.58 million | Q1 2015: $35.53 million | Q2 2015: $32.47 million | Q3 2015: $29.04 million | Q1 2016: $22.22 million | Q2 2016: $18.81 million | Q3 2016: $15.78 million | Q1 2017: $8.78 million | Q2 2017: $5.10 million | Q3 2017: $1.76 million | Q1 2018: -$313.2 thousand | Q2 2018: -$332.0 thousand | Q3 2018: -$375.6 thousand | Q4 2018: $2.46 million | Q1 2019: $2.50 million | Q2 2019: $5.62 million | Q3 2019: $4.80 million | Q1 2020: $15.11 million | Q2 2020: $15.80 million | Q3 2020: $14.89 million | Q1 2021: $9.95 million | Q2 2021: $8.91 million | Q3 2021: $8.01 million | Q1 2022: $6.36 million | Q2 2022: $24.36 million | Q3 2022: $24.19 million | Q1 2023: $18.75 million | Q2 2023: $12.32 million | Q3 2023: $12.55 million | Q1 2024: $11.83 million | Q2 2024: $12.16 million | Q3 2024: $8.85 million | Q4 2024: $8.25 million | Q1 2025: $8.02 million | Q2 2025: $8.30 million | Q3 2025: $9.05 million.
- Over the full 17 years of available data (2008 to 2024), Oncotelic Therapeutics, Inc.'s Stockholders Equity has declined by 71.3%.
- Historical annual values: Fiscal year 2024: $8.25 million | Fiscal year 2023: $12.13 million | Fiscal year 2022: $19.41 million | Fiscal year 2021: $7.96 million | Fiscal year 2020: $11.77 million | Fiscal year 2019: $16.90 million | Fiscal year 2018: $2.46 million | Fiscal year 2017: -$483.6 thousand | Fiscal year 2016: $12.50 million | Fiscal year 2015: $25.35 million | Fiscal year 2014: $29.00 million | Fiscal year 2013: $6.04 million | Fiscal year 2012: $4.55 million | Fiscal year 2011: $8.80 million | Fiscal year 2010: -$5.26 million | Fiscal year 2009: $5.80 million | Fiscal year 2008: $28.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: